If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

AstraZeneca (AZ) has shared positive results from a phase 3b study of its anti-inflammatory reliever rescue therapy Airsupra ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supp ...

Patients with moderate to severe asthma saw increases in FEV1 within 24 hours after taking a loading dose of rademikibart, ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently S ...

Asthma is a chronic condition that never completely goes away, but you can manage your symptoms and achieve remission. According to the Centers for Disease Control and Prevention (CDC), an ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial” or the "Company”), a clinical-stage biopharmaceutical company focused on ...

Hitgen Ltd. has prepared and tested interleukin-17 receptor A (IL17RA; CD217) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, asthma, multiple sclerosis, ...